Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17 2022 - 4:01PM
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage
cell therapy company developing therapies with the potential to
transform the standard of care in solid organ transplantation and
severe immune and blood disorders, today announced today announced
that Scott Requadt, Chief Executive Officer of Talaris, will be
presenting virtually at the H.C. Wainwright Global Investment
Conference being held May 23-25, 2022.
A webcast of the pre-recorded on-demand presentation will be
made available Tuesday, May 24th starting at 7:00 AM ET, and can be
accessed by visiting the investors section of the Talaris website
at www.talaristx.com. The event will remain archived on the Talaris
website for 90 days.
About Talaris TherapeuticsTalaris Therapeutics,
Inc. is a late-clinical stage cell therapy company developing
therapies with the potential to transform the standard of care in
solid organ transplantation and severe immune and blood disorders.
Talaris maintains corporate offices in Boston, MA, its cell
processing facility in Louisville, KY, and additional research
operations in Houston, TX.
Media ContactLisa RaffenspergerTen Bridge
Communicationslisa@tenbridgecommunications.com(617)
903-8783
Investor ContactChris BrinzeyICR
Westwickechris.brinzey@westwicke.com (339)
970-2843
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Apr 2023 to Apr 2024